Practical considerations for establishing dead-time corrections in quantitative SPECT imaging

Quantitative SPECT studies require specific information about the equipment being used. Particularly in the context of therapeutic studies, the effect of dead-time can be significant and must be quantified. We explored different techniques for measuring the dead-time constant and applying dead-time corrections to the data. Method: The dead-time constant was measured on four similar SPECT/CT systems by following the response of the system to a uniform phantom initially containing 17 GBq of Lu-177 over a period of 23 days. It was then calculated using the two-source method with 1 332 MBq of Tc-99 m. The dead-time constant found was used to correct SPECT/CT phantom images either applying the correction by projection or globally on the image. Results: Both methods of calculating the dead-time constant produced equivalent results. However, the dead-time constant varied by as much as 8% between machines of the same model and manufacturer. Correcting for dead-time by projection rather than globally produced slightly more precise results (0.94% error rather than 2.59% error). The benefit of this correction technique will be dependent on the level of asymmetry in the patient as well as the magnitude of the dead-time correction effect. Conclusion: quantification of the dead-time of a system can be performed quickly using the two-source method and any radioisotope. However, it is important to perform this measurement on every system being used. In vastly asymmetric images with high dead-time correction, correcting for dead-time by projection can be pertinent, increasing the precision of dosimetry calculations by several percent. However this additional gain may be within the error of SUV measurements for many clinical acquisitions.

• Publication year

  2020

• Venue

  Biomedical engineering and physics express

• Publication date

  2020-02-24

• Fields of study

  Medicine, Physics, Computer Science

• Identifiers
  DOI 10.1088/2057-1976/ab7500PMID 33438643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

  2017cited by this paper
• Voxel-level dosimetry of 177Lu-octreotate: from phantoms to patients

  2017cited by this paper
• Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

  2016cited by this paper
• MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy

  2016cited by this paper
• Evaluation of dead-time corrections for post-radionuclide-therapy 177Lu quantitative imaging with low-energy high-resolution collimators

  2014cited by this paper
• Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

  2011cited by this paper
• Acceleration of Monte Carlo-based scatter compensation for cardiac SPECT

  2008cited by this paper
• Deadtime measurements in scintillation cameras under scatter conditions simulating quantitative nuclear cardiography.

  1978cited by this paper

• Impact of improved dead time correction on the quantification accuracy of a dedicated BrainPET scanner

  2024cites this paper
• Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy

  2022cites this paper
• Dosimetry-Guided Radiopharmaceutical Therapy

  2021cites this paper